CommercialCoverageLow impact
08.00.10e, Luspatercept–aamt (Reblozyl®)
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Mar 23, 2026
We identified it
Jun 19, 2026
Summary
The medical necessity criteria and medical coding requirements for Luspatercept-aamt (Reblozyl®) have been updated. This affects billing and coverage determination for this specialty medication used to treat anemia in certain blood disorders.
Action Required
By March 23, 2026: Billing team must review updated medical necessity criteria for Luspatercept-aamt (Reblozyl®) at the provided policy URL. Update prior authorization processes and documentation requirements for this specialty medication. Ensure providers are aware of any new coding or coverage criteria to prevent claim denials.